Nothing Special   »   [go: up one dir, main page]

MX2021015501A - Anticuerpos y metodos de uso. - Google Patents

Anticuerpos y metodos de uso.

Info

Publication number
MX2021015501A
MX2021015501A MX2021015501A MX2021015501A MX2021015501A MX 2021015501 A MX2021015501 A MX 2021015501A MX 2021015501 A MX2021015501 A MX 2021015501A MX 2021015501 A MX2021015501 A MX 2021015501A MX 2021015501 A MX2021015501 A MX 2021015501A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
therapeutic proteins
slamf6
directed against
Prior art date
Application number
MX2021015501A
Other languages
English (en)
Inventor
Arnima Bisht
James Ackroyd
Original Assignee
Oxford Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biotherapeutics Ltd filed Critical Oxford Biotherapeutics Ltd
Publication of MX2021015501A publication Critical patent/MX2021015501A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos y otras proteínas terapéuticas dirigidas contra el miembro 6 de la familia SLAM (SLAMF6), conocido también como NTB-A o CD352, ácidos nucleicos que codifican estos anticuerpos y proteínas terapéuticas, métodos para preparar los anticuerpos y otras proteínas terapéuticas, y métodos para el tratamiento de enfermedades como el cáncer usando los anticuerpos y otras proteínas terapéuticas dirigidas contra SLAMF6.
MX2021015501A 2019-07-03 2020-07-02 Anticuerpos y metodos de uso. MX2021015501A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870269P 2019-07-03 2019-07-03
US202062965450P 2020-01-24 2020-01-24
PCT/GB2020/051588 WO2021001653A1 (en) 2019-07-03 2020-07-02 Antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2021015501A true MX2021015501A (es) 2022-04-20

Family

ID=71575476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015501A MX2021015501A (es) 2019-07-03 2020-07-02 Anticuerpos y metodos de uso.

Country Status (12)

Country Link
US (1) US20220372137A1 (es)
EP (1) EP3994172A1 (es)
JP (1) JP2022537703A (es)
KR (1) KR20220030937A (es)
CN (1) CN114008077B (es)
AU (1) AU2020298833A1 (es)
BR (1) BR112021024997A2 (es)
CA (1) CA3143087A1 (es)
IL (1) IL288886A (es)
MX (1) MX2021015501A (es)
WO (1) WO2021001653A1 (es)
ZA (1) ZA202110285B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4281474A2 (en) * 2021-01-21 2023-11-29 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
WO2024059854A2 (en) * 2022-09-16 2024-03-21 The Trustees Of Columbia University In The City Of New York Bispecific antibody for t-cell modulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5576423A (en) * 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
CA2453822C (en) 2001-08-03 2011-02-22 Tyco Healthcare Group Lp Tissue marking apparatus and method
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
HUE030079T2 (en) 2004-09-23 2017-04-28 Genentech Inc Cysteine-manipulated antibodies and conjugates
WO2008027739A2 (en) 2006-08-28 2008-03-06 Nuvelo, Inc. Antibodies to ntb-a
MX2009002418A (es) * 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
JP6449777B2 (ja) 2012-12-21 2019-01-09 シアトル ジェネティックス， インコーポレイテッド 抗ｎｔｂ−ａ抗体ならびに関連する組成物および方法
EP4101461A1 (en) 2014-01-09 2022-12-14 Hadasit Medical Research Services and Development Ltd. Improved cell compositions and methods for cancer therapy
EP3209688A1 (en) * 2014-10-23 2017-08-30 Five Prime Therapeutics, Inc. Slamf1 antagonists and uses thereof
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017004330A1 (en) 2015-06-30 2017-01-05 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods

Also Published As

Publication number Publication date
EP3994172A1 (en) 2022-05-11
CA3143087A1 (en) 2021-01-07
KR20220030937A (ko) 2022-03-11
CN114008077A (zh) 2022-02-01
CN114008077B (zh) 2024-10-29
IL288886A (en) 2022-02-01
AU2020298833A1 (en) 2022-01-20
BR112021024997A2 (pt) 2022-01-25
WO2021001653A1 (en) 2021-01-07
US20220372137A1 (en) 2022-11-24
ZA202110285B (en) 2023-10-25
JP2022537703A (ja) 2022-08-29

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12020551907A1 (en) Antagonizing cd73 antibody
NZ754051A (en) Novel antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
ZA202110285B (en) Antibodies and methods of use
MX2021004454A (es) Anticuerpos anti-sinucleina.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
SA521431223B1 (ar) Angpt2 أجسام مضادة لـ
MX2022003523A (es) Proteinas de union a antigenos.
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
EA202092121A1 (ru) Антитела против cd73 и их применения
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
MX2024005336A (es) Composiciones y metodos para la modulacion de inmunidad mediada por cadena beta.
EA202191922A1 (ru) Способы и композиции для лечения злокачественных опухолей
WO2024173352A3 (en) Methods of treating cancer with a sirp1a-based chimeric protein
MX2024009726A (es) Anticuerpos anti-il13ra2 y usos de estos.